US 11,806,384 B2
Stem cell stimulating compositions for treatment of melasma
Nikolay Turovets, Carlsbad, CA (US)
Assigned to MEDICELL TECHNOLOGIES, LLC, Carlsbad, CA (US)
Filed by MEDICELL TECHNOLOGIES, LLC, Carlsbad, CA (US)
Filed on Apr. 30, 2021, as Appl. No. 17/245,360.
Application 17/245,360 is a division of application No. 16/062,864, granted, now 11,020,452, previously published as PCT/US2015/065870, filed on Dec. 15, 2015.
Prior Publication US 2021/0244794 A1, Aug. 12, 2021
Int. Cl. A61K 38/17 (2006.01); A61K 8/64 (2006.01); A61Q 19/02 (2006.01); A61K 8/14 (2006.01); A61K 8/44 (2006.01); A61K 8/55 (2006.01); A61K 8/65 (2006.01); A61K 9/00 (2006.01); A61K 31/198 (2006.01); A61K 31/66 (2006.01); A61K 38/18 (2006.01); A61K 38/38 (2006.01); A61K 38/39 (2006.01); A61K 45/06 (2006.01); A61M 37/00 (2006.01); A61N 5/06 (2006.01); A61N 5/067 (2006.01)
CPC A61K 38/1729 (2013.01) [A61K 8/14 (2013.01); A61K 8/442 (2013.01); A61K 8/553 (2013.01); A61K 8/64 (2013.01); A61K 8/65 (2013.01); A61K 9/0014 (2013.01); A61K 31/198 (2013.01); A61K 31/66 (2013.01); A61K 38/1808 (2013.01); A61K 38/1825 (2013.01); A61K 38/38 (2013.01); A61K 38/39 (2013.01); A61K 45/06 (2013.01); A61M 37/0015 (2013.01); A61M 37/0092 (2013.01); A61N 5/062 (2013.01); A61Q 19/02 (2013.01); A61K 2800/91 (2013.01); A61M 2037/0007 (2013.01); A61M 2037/0023 (2013.01); A61M 2037/0061 (2013.01); A61N 5/067 (2021.08)] 12 Claims
 
1. A kit for treating an extant melasma lesion, comprising:
a mask comprising a cosmetically acceptable carrier;
a cream comprising a cosmetically acceptable carrier in combinations with a first defensin in a sub-antimicrobial concentration of the first defensin that is effective to reduce pigmentation of the extant melasma lesion on application to the extant melasma lesion as a cream formulation; and
a serum comprising a cosmetically acceptable carrier in combination with a first defensin in a sub-antimicrobial concentration of the first defensin that is effective to reduce pigmentation of the extant melasma lesion on application to the extant melasma lesion as a serum formulation.